Skip to main content
. 2023 May 8;58(8):893–906. doi: 10.1038/s41409-023-01997-3

Fig. 4. Graft-versus-host disease-free, relapse-free survival based on matched unrelated donor age.

Fig. 4

Unadjusted probabilities of GRFS following allogeneic HCT using MSDs, younger or older 8/8 MUDs, and younger or older 7/8 MUDs using different thresholds of donor age among MUDs (30 [a], 35 [b], 40 [c], and 45 [d] years) for patients with MDS over 50 years of age.